A National Hepatitis C Elimination Program in the United States: A Historic Opportunity

Rachael L Fleurence; Francis S Collins

doi:10.1001/jama.2023.3692

A National Hepatitis C Elimination Program in the United States: A Historic Opportunity

JAMA. 2023 Apr 18;329(15):1251-1252. doi: 10.1001/jama.2023.3692.

Authors

Rachael L Fleurence¹, Francis S Collins¹

Affiliation

¹ Executive Office of the President, The White House, Washington, DC.

PMID: 36892976
DOI: 10.1001/jama.2023.3692

No abstract available

Plain language summary

This Viewpoint introduces a proposed 5-year program from the Biden-Harris administration that would use direct-acting antivirals to eliminate hepatitis C in the United States.

MeSH terms

Antiviral Agents* / therapeutic use
Disease Eradication* / methods
Hepacivirus
Hepatitis C* / drug therapy
Hepatitis C* / epidemiology
Hepatitis C* / prevention & control
Hepatitis C, Chronic* / drug therapy
Hepatitis C, Chronic* / epidemiology
Hepatitis C, Chronic* / prevention & control
Humans
United States / epidemiology

Substances

Antiviral Agents